


Protein-Arginine-Deiminase-Inhibitors-Modulators-MCE.docx 免費下載
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
1、 HYPERLINK https:/www.MedChemE/Targets/Protein Arginine Deiminase.html Protein HYPERLINK https:/www.MedChemE/Targets/Protein Arginine Deiminase.html HYPERLINK https:/www.MedChemE/Targets/Protein Arginine Deiminase.html Arginine HYPERLINK https:/www.MedChemE/Targets/Protein Arginine Deiminase.html HY
2、PERLINK https:/www.MedChemE/Targets/Protein Arginine Deiminase.html DeiminasePeptidylarginine DeiminaseProtein arginine deiminase (PAD), is a group of calcium-dependent enzymes, which play crucial roles in citrullination, and cancatalyze arginine residues into citrulline. his chemical reaction induc
3、es citrullinated proteins formation with altered structure andfunction, leading to numerous pathological diseases, including inflammation and autoimmune diseases. These pathologiesestablished the PADs as therapeutic targets and multiple PAD inhibitors are known.Humans encode five PADs, designated PA
4、Ds 1-4 and PAD6. Of the five PAD isozymes (PAD1, 2, 3, 4 and 6), only four (PADs1-4) arecatalytically active. PAD activity is tightly regulated by Ca2+ and PADs contain 4 (PAD1), 5 (PAD3, 4) or 6 (PAD2) Ca2+-binding sites.Dysregulated PAD activity, most notably PAD2 and PAD4, is associated with mult
5、iple inflammatory diseases (e.g., rheumatoidarthritis) as well as cancer, and PAD inhibitors, such as Cl-amidine and BB-Cl-amidine, show efficacy in multiple preclinical animalmodels of disease.www.MedChemE 1 HYPERLINK https:/www.MedChemE/Targets/Protein Arginine Deiminase.html Protein HYPERLINK htt
6、ps:/www.MedChemE/Targets/Protein Arginine Deiminase.html HYPERLINK https:/www.MedChemE/Targets/Protein Arginine Deiminase.html Arginine HYPERLINK https:/www.MedChemE/Targets/Protein Arginine Deiminase.html HYPERLINK https:/www.MedChemE/Targets/Protein Arginine Deiminase.html Deiminase HYPERLINK http
7、s:/www.MedChemE/Targets/Protein Arginine Deiminase.html HYPERLINK https:/www.MedChemE/Targets/Protein Arginine Deiminase.html Inhibitors HYPERLINK https:/www.MedChemE/Targets/Protein Arginine Deiminase.html HYPERLINK https:/www.MedChemE/Targets/Protein Arginine Deiminase.html & HYPERLINK https:/www.
8、MedChemE/Targets/Protein Arginine Deiminase.html HYPERLINK https:/www.MedChemE/Targets/Protein Arginine Deiminase.html Activators HYPERLINK https:/www.MedChemE/Acefylline.html Acefylline(Theophyllineacetic acid; Theophylline-7-acetic acid) Cat. No.: HY-B1505 HYPERLINK https:/www.MedChemE/BB-Cl-Amidi
9、ne.html BB-Cl-AmidineCat. No.: HY-111347Acefylline (Theophyllineacetic acid), a xanthinederivative, is an adenosine receptor antagonist.Acefylline is a peptidylarginine deiminase (PAD)activator. Acefylline is also a bronchodilator,which inhibits rat lung cAMP phosphodiesteraseisoenzymes.BB-Cl-Amidin
10、e is a peptidylarginine deminase(PAD) inhibitor.Purity: 99.89%Clinical Data: LaunchedSize: 10 mM 1 mL, 100 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/bb-cl-amidine-hydrochloride.html BB-Cl-Amidine HYPERLINK https:/www.MedChemE/bb-cl-amidine-hydr
11、ochloride.html HYPERLINK https:/www.MedChemE/bb-cl-amidine-hydrochloride.html hydrochloride HYPERLINK https:/www.MedChemE/bb-cl-amidine-hydrochloride.html HYPERLINK https:/www.MedChemE/bms-p5.html BMS-P5Cat. No.: HY-111347A Cat. No.: HY-137655BB-Cl-Amidine hydrochloride is a peptidylargininedeminase
12、 (PAD) inhibitor.BMS-P5 is a specific and orally activepeptidylarginine deiminase 4 (PAD4) inhibitor.BMS-P5 blocks MM-induced NET formation and delaysprogression of MM in a syngeneic mouse model.Purity: 99.78%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mgPurity: 98%Clinic
13、al Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/bms-p5-free-base.html BMS-P5 HYPERLINK https:/www.MedChemE/bms-p5-free-base.html HYPERLINK https:/www.MedChemE/bms-p5-free-base.html free HYPERLINK https:/www.MedChemE/bms-p5-free-base.html HYPERLINK https:/www.MedChemE/b
14、ms-p5-free-base.html base HYPERLINK https:/www.MedChemE/bms-p5-free-base.html HYPERLINK https:/www.MedChemE/Cl-amidine.html Cl-amidineCat. No.: HY-137655A Cat. No.: HY-100574BMS-P5 free base is a specific and orally activepeptidylarginine deiminase 4 (PAD4) inhibitor.BMS-P5 free base blocks MM-induc
15、ed NET formationand delays progression of MM in a syngeneic mousemodel.Cl-amidine is an orally active peptidylargininedeminase (PAD) inhibitor, with IC values of 0.850M, 6.2 M and 5.9 M for PAD1, PAD3, and PAD4,respectively. Cl-amidine induces apoptosis incancer cells.Purity: 99.96%Clinical Data: No
16、 Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/Cl-amidine_hydrochloride.html Cl-amidine HYPERLINK https:/www.MedChemE/Cl-amidine_hydrochloride.html HYPERLINK https:/www.MedChemE/Cl-amidin
17、e_hydrochloride.html hydrochloride HYPERLINK https:/www.MedChemE/Cl-amidine_hydrochloride.html HYPERLINK https:/www.MedChemE/cl-amidine-tfa.html Cl-amidine HYPERLINK https:/www.MedChemE/cl-amidine-tfa.html HYPERLINK https:/www.MedChemE/cl-amidine-tfa.html TFACat. No.: HY-100574A Cat. No.: HY-100574B
18、Cl-amidine hydrochloride is an orally activepeptidylarginine deminase (PAD) inhibitor, withIC values of 0.8 M, 6.2 M and 5.9 M for PAD1,50PAD3, and PAD4, respectively. Cl-amidinehydrochloride induces apoptosis in cancer cells.Cl-amidine TFA is an orally active peptidylargininedeminase (PAD) inhibito
19、r, with IC values of 0.850M, 6.2 M and 5.9 M for PAD1, PAD3, and PAD4,respectively. Cl-amidine TFA induces apoptosis incancer cells.Purity: 99.10%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg
20、 HYPERLINK https:/www.MedChemE/d-cl-amidine.html D-Cl-amidine HYPERLINK https:/www.MedChemE/d-cl-amidine.html HYPERLINK https:/www.MedChemE/d-cl-amidine-hydrochloride.html D-Cl-amidine HYPERLINK https:/www.MedChemE/d-cl-amidine-hydrochloride.html HYPERLINK https:/www.MedChemE/d-cl-amidine-hydrochlor
21、ide.html hydrochlorideCat. No.: HY-100574C Cat. No.: HY-100574DD-Cl-amidine is a potent and highly selectivePAD1 inhibitor. D-Cl-amidine is well-torelatedwith no significant toxicity.D-Cl-amidine hydrochloride is a potent and highlyselective PAD1 inhibitor. D-Cl-amidine iswell-torelated with no sign
22、ificant toxicity.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 99.40%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg2 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMedChemE HYPERLINK https:/www.MedChemE/gsk106.html GSK106 HYPERLINK https:/ww
23、w.MedChemE/gsk106.html HYPERLINK https:/www.MedChemE/gsk121.html GSK121Cat. No.: HY-120343 Cat. No.: HY-117777GSK106 is an inactive control for the selectivePAD4 inhibitors, GSK484 and GSK199.GSK-121 Trifluoroacetates a selective PAD4inhibitor.Purity: 98%Clinical Data: No Development ReportedSize: 1
24、 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/gsk199.html GSK199 HYPERLINK https:/www.MedChemE/gsk199.html HYPERLINK https:/www.MedChemE/GSK484.html GSK484 HYPERLINK https:/www.MedChemE/GSK484.html HYPERLINK https:/www.MedChemE/GSK484.html h
25、ydrochlorideCat. No.: HY-103058 Cat. No.: HY-100514GSK199 is a reversible and selective PAD4inhibitor with an IC of 200 nM in the absence of50calcium.GSK484 hydrochloride is a selective and reversiblepeptidylarginine deiminase 4 (PAD4) inhibitor.GSK484 hydrochloride demonstrates high affinitybinding
26、 to PAD4 with IC s of 50 nM in the absence50of Calcium. In the presence of 2 mM Calcium,notably lower potency (250 nM) is observed.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98.76%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/pad2-in-1.html PAD2-IN-1 HYPERLINK https:/www.MedChemE/pad2-in-1.html HYPERLINK https:/www.MedChemE/pad2-in-2.html PAD2-IN-2Cat. No.: HY-136557 Cat. No.: HY-125099PAD2-IN-1
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 衡水高二上數(shù)學(xué)試卷
- 衡陽市三年級數(shù)學(xué)試卷
- 貴州近五年中考數(shù)學(xué)試卷
- 2025年中國金絲楠木市場深度評估及行業(yè)投資前景咨詢報告
- 中國微波菱形盆行業(yè)市場發(fā)展前景及發(fā)展趨勢與投資戰(zhàn)略研究報告(2024-2030)
- 2025屆重慶市彭水一中高一物理第二學(xué)期期末復(fù)習(xí)檢測試題含解析
- 醫(yī)療美容監(jiān)督管理課件
- 落實董事會職權(quán)管理辦法
- 融媒體運營中心管理辦法
- 衡陽縣人口管理辦法規(guī)定
- 工程勘察設(shè)計實施要點
- 備戰(zhàn)2025年中考英語時文閱讀2(含答案)
- 農(nóng)戶果樹租賃合同范例
- 2025年安全意識培訓(xùn)試題及答案
- DF3382EF備用電源自動投入裝置技術(shù)說明書(第三版藍(lán)圖說明書對應(yīng)程序Ver4.04.004)
- 平安銀行擔(dān)保合同
- 2025年秋季學(xué)期初中安全工作計劃
- 弱電桿線下地遷移施工方案
- 2025年行政執(zhí)法證考試必考題庫及答案(共四套)
- 獸醫(yī)公共衛(wèi)生概論期末復(fù)習(xí)資料
- 湖南省張家界市(2024年-2025年小學(xué)六年級語文)部編版期末考試((上下)學(xué)期)試卷及答案
評論
0/150
提交評論